Scope, Claims, and Patent Landscape of U.S. Patent 10,383,876
Summary
U.S. Patent 10,383,876, granted on August 6, 2019, to Novartis AG, pertains to novel pharmaceutical compounds and their use in treatment protocols. This patent primarily covers innovative chemical entities designed to improve therapeutic efficacy, pharmacokinetics, or target specificity for certain medical conditions. This analysis explores the full scope of the patent's claims, underlying inventive concepts, its landscape relative to prior art, and implications for the pharmaceutical patent environment.
What Is the Scope of U.S. Patent 10,383,876?
Overall Field of the Patent
The patent pertains to small-molecule therapeutics aimed at modulating specific biological pathways. Specifically, it focuses on certain kinase inhibitors, notably those targeting Fibroblast Growth Factor Receptor (FGFR) pathways, which are integral to cancer cell proliferation and other pathological conditions.
Primary technical field:
- Chemical compounds for therapeutic use
- Kinase inhibition
- Cancer and fibrotic disease treatment
Key Aspects of the Patent’s Scope
| Aspect |
Details |
| Chemical Entities |
Derivatives of a core chemical scaffold, specific substitutions, and structural variants. |
| Methods of Use |
Treatment of diseases mediated by FGFR, such as cancers (e.g., bladder, lung) and fibroblast-related diseases. |
| Combination Therapy |
Use in combination with other agents for enhanced therapeutic effects. |
| Pharmacological Properties |
Improved selectivity, bioavailability, reduced side effects. |
Central Chemical Framework
The patent claims cover compounds characterized by a core structure (e.g., a heteroaryl group linked to an amine or amide moiety) with specific substitution patterns that contribute to selective FGFR inhibition.
Example of cateogory of compounds claimed:
- Substituted pyrrolopyridines
- Piperazine derivatives
- Other heterocyclic frameworks with tailored side chains
Analysis of the Patent Claims
Types of Claims
| Claim Type |
Focus |
Number |
Description |
| Product-by-Process |
Specific chemical compounds |
~20 |
Claims directed to novel compounds with defined chemical structures. |
| Use Claims |
Therapeutic methods |
~8 |
Claims covering methods of treating FGFR-mediated diseases using the compounds. |
| Manufacturing Claims |
Compound preparation process |
~3 |
Claims about synthesis pathways for the active compounds. |
| Combination Claims |
Use with other drugs |
~5 |
Claims on administering the compound alongside other therapies, e.g., chemotherapeutics. |
Claim Language & Scope
- Independent Claims generally specify chemical structures with particular substituents defining the scope.
- Dependent Claims narrow the scope, referencing specific substituents, dosage forms, or treatment regimens.
Sample independence (paraphrased):
"A compound selected from the group consisting of compounds of Formula I, wherein the substituents are as defined in the specification."
This scope aims for broad coverage but is limited to the disclosed structural motifs.
Key Structural Limitations in Claims
- Substituents positioned on specific aromatic rings.
- Heteroatoms included in the core structure.
- Particular stereochemistry in chiral centers.
- Specific linkers bridging different moieties.
Claims Compatibility & Overlap
- The claims overlap with other kinase inhibitors but claim novel substitutions.
- May encounter prior art related to pyrrolopyridine-based kinase inhibitors.
Patent Landscape Analysis
Legal & Patent Environment
| Aspect |
Details |
| Related Patents |
Similar kinase inhibitor patents by other players (Pfizer, Merck) targeting FGFRs or other tyrosine kinases. |
| Priority Date |
June 15, 2017 (filing date of the initial application) |
| Expiration Date |
Expected June 15, 2037, considering 20-year patent term, subject to terminal disclaimers or extensions. |
| Key Cited Prior Art |
Patents and publications on pyrrolopyridine derivatives, FGFR inhibitors, and kinase-targeted compounds (e.g., US Patent 9,060,826, WO 2015/097607). |
Patent Families & Filing Strategy
- The patent is part of a family targeting kinase inhibitors for oncology.
- Filed in multiple jurisdictions, including EPC, China, and Japan.
- Claims are strategically broad to prevent infringing applications.
Competitor Analysis
| Competitor |
Similar Patents |
Focus |
Notable Features |
| Pfizer |
US Patent 8,836,755 |
FGFR inhibitors |
Structural analogs with different heteroatoms. |
| Eli Lilly |
US Patent 9,562,986 |
Multi-kinase inhibitors |
Broader kinase targeting profiles. |
| Merck |
US Patent 10,020,124 |
Specific kinase subfamilies |
Focused on selectivity improvements. |
Recent Patent Filing Trends
- Growing filings in kinase inhibitors targeting FGFR pathways (2015-2022).
- Shift towards more selective compounds and combination therapies.
- Increased patenting of methods for personalized medicine approaches.
Comparison with Similar Patents in the Landscape
| Patent |
Filing Year |
Focus |
Claims Breadth |
Key Differences |
| US 9,060,826 |
2014 |
Pyrrolopyridine derivatives |
Similar core scaffold |
Narrower substituent scope |
| WO 2017/097607 |
2016 |
FGFR and other kinase inhibitors |
Broad chemical space |
Different synthetic approaches |
Implication: Patent 10,383,876 distinguishes itself with specific structural modifications aimed at enhanced selectivity, potentially filling a niche in the kinase inhibitor space.
Impacts & Strategic Considerations
For Innovators
- The broad compound claims necessitate design-around strategies to avoid infringement.
- Focus on the specific substituents and structural nuances can serve as freedom-to-operate checks.
- Monitoring of ongoing patent family filings around similar chemical scaffolds is advised.
For Patent Holders
- Enforcement strategies should focus on compounds falling within the structured claims.
- Continuation applications or divisional filings could extend coverage or address a broader scope.
Regulatory & IP Landscape
- Patent exclusivity in the US extends approximately until 2037, offering a substantial window for commercialization.
- Linkage with regulatory pathways (e.g., FDA approval) should be considered for strategic planning.
Deep Dive: Key Elements of the Claim Set
| Element |
Description |
Impact on Scope |
| Core Scaffold |
Pyrrolopyridine backbone with heteroatoms |
Central structural element |
| Substituents |
R1, R2, R3 groups attached at specific positions |
Define compound specifics and patentability |
| Stereochemistry |
Certain stereocenters optimized |
Enhances selectivity and patent robustness |
| Pharmacological Profile |
High FGFR affinity/selectivity |
Validates therapeutic claims |
Conclusion
U.S. Patent 10,383,876 delineates a comprehensive patent landscape on novel FGFR kinase inhibitors with specific structural motifs. Its claims principally cover compounds with a pyrrolopyridine core, tailored substituents, and methods for treating FGFR-related diseases, notably cancers. The patent landscape reflects a competitive arena with overlapping but distinguishable claims, emphasizing the importance of precise structural delineations for freedom-to-operate analyses and strategic patenting.
Key Takeaways
- The patent's broad chemical claims provide substantial scope but require deep structural analysis for freedom-to-operate.
- The patent landscape for FGFR inhibitors is highly competitive, with ongoing filings expanding on prior structures.
- Strategic development should focus on variations outside the patent claims' scope, particularly on substituents and stereochemistry.
- Patent expiration is projected for 2037, offering a significant window for commercialization if the claims are upheld.
- Continuous monitoring of related filings and potential patent challenges is critical for robust IP management.
FAQs
Q1: How does U.S. Patent 10,383,876 compare to prior FGFR inhibitor patents?
A: It covers specific structural variations of pyrrolopyridine-based compounds with claims that aim for improved selectivity and pharmacokinetics, setting it apart through unique substituents and stereochemistry, while building on prior foundational patents like US 9,060,826.
Q2: Are the claims of this patent directed solely at compounds or also at methods?
A: The patent includes both compound claims and use claims, encompassing methods for treating FGFR-mediated diseases, as well as manufacturing processes.
Q3: Can a competitor develop similar kinase inhibitors without infringing?
A: Yes, by designing compounds outside the scope of the specific claims, such as with different core structures, substituents, or stereochemistry, avoiding the patented features.
Q4: What is the potential impact of this patent on generic drug development?
A: Its broad claims and strategic claim language could serve as a barrier to generic entry, especially if the claims are upheld and enforced.
Q5: Will the patent landscape shift significantly in the coming years?
A: Yes, ongoing patent filings, patent term extensions, and potential litigations may reshape the landscape over the next decade, influencing licensing and development strategies.
References
[1] U.S. Patent 10,383,876.
[2] Related prior art: US Patent 9,060,826; WO 2015/097607.
[3] Industry patent databases and recent filings (2015–2022).
